Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab rezetecan (SHR-A1811) plus bevacizumab in previously treated HER2-altered NSCLC
ChiCTR2500113565Phase 2Not yet recruiting
- Sponsor
- Cancer Hospital, Chinese Academy of Medical Sciences
- Start
- Dec 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trastuzumab rezetecan and bevacizumab in Non-small cell lung cancer (NSCLC), sponsored by Cancer Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Progression-free survival. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
trastuzumab rezetecanbevacizumab
03
Conditions
Non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2500113565.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500113565.